| Sumario: | The article focuses on the use of medicinal cannabis for managing migraine disorders, highlighting its potential therapeutic benefits and associated risks. Migraines, which disproportionately affect women and people of color, present significant challenges due to barriers in diagnosis and treatment, prompting some sufferers to turn to cannabis products containing tetrahydrocannabinol (THC) and cannabidiol (CBD) for relief. While evidence suggests cannabis may reduce migraine intensity and related symptoms, concerns remain about health risks, regulatory inconsistencies, and limited clinical guidance. The article emphasizes the ethical responsibilities of social workers, as outlined by the National Association of Social Workers (NASW), to provide clients with accurate medical information, respect self-determination, and refer to qualified healthcare providers without offering medical advice on cannabis use.
|
|---|